Patient baseline characteristics
| . | Overall cohort . | No ATG . | ATG . | P . |
|---|---|---|---|---|
| N (%) . | N (%) . | N (%) . | ||
| Total enrolled and treated, n (%) | 687 (100) | 420 (100) | 267 (100) | |
| Median age at HCT (range) | 50 (16-76) | 48 (16-73) | 55 (18-76) | <.0001 |
| Male gender, n (%) | 346 (51) | 228 (54) | 118 (44) | .0121 |
| Acute myeloid leukemia | 687 (100) | 420 (100) | 267 (100) | |
| First CR,* n (%) | 293 (43) | 164 (39) | 129 (48) | .017 |
| Advanced disease stages,† n (%) | 394 (57) | 256 (61) | 138 (52) | |
| Cytomegalovirus serostatus constellation, n (%) | ||||
| D+/R− | 52 (8) | 29 (7) | 23 (9) | <.0001 |
| D+/R+ | 285 (41) | 172 (41) | 113 (42) | |
| D−/R+ | 147 (21) | 76 (18) | 71 (27) | |
| D−/R− | 203 (30) | 143 (34) | 60 (22) | |
| Donor-recipient constellations | ||||
| MRD | 214 (31) | 214 (51) | 0 (0) | <.0001 |
| MUD | 424 (62) | 198 (47) | 226 (85) | |
| MMUD | 49 (7) | 8 (2) | 41 (15) | |
| D/R gender: f/m | 77 (11) | 58 (14) | 19 (7) | .0063 |
| Other | 610 (89) | 362 (86) | 248 (93) | |
| Donor age, median (95% CI) | 38 (20-64) | 41 (22-64) | 32 (20-52) | <.0001 |
| Graft source | ||||
| PBSC | 617 (90) | 365 (87) | 255 (96) | <.0001 |
| BM | 67 (10) | 55 (13) | 12 (4) | |
| Conditioning | ||||
| MAC | 272 (40) | 226 (54) | 46 (17) | <.0001 |
| RIC | 412 (60) | 191 (46) | 221 (83) | <.0001 |
| . | Overall cohort . | No ATG . | ATG . | P . |
|---|---|---|---|---|
| N (%) . | N (%) . | N (%) . | ||
| Total enrolled and treated, n (%) | 687 (100) | 420 (100) | 267 (100) | |
| Median age at HCT (range) | 50 (16-76) | 48 (16-73) | 55 (18-76) | <.0001 |
| Male gender, n (%) | 346 (51) | 228 (54) | 118 (44) | .0121 |
| Acute myeloid leukemia | 687 (100) | 420 (100) | 267 (100) | |
| First CR,* n (%) | 293 (43) | 164 (39) | 129 (48) | .017 |
| Advanced disease stages,† n (%) | 394 (57) | 256 (61) | 138 (52) | |
| Cytomegalovirus serostatus constellation, n (%) | ||||
| D+/R− | 52 (8) | 29 (7) | 23 (9) | <.0001 |
| D+/R+ | 285 (41) | 172 (41) | 113 (42) | |
| D−/R+ | 147 (21) | 76 (18) | 71 (27) | |
| D−/R− | 203 (30) | 143 (34) | 60 (22) | |
| Donor-recipient constellations | ||||
| MRD | 214 (31) | 214 (51) | 0 (0) | <.0001 |
| MUD | 424 (62) | 198 (47) | 226 (85) | |
| MMUD | 49 (7) | 8 (2) | 41 (15) | |
| D/R gender: f/m | 77 (11) | 58 (14) | 19 (7) | .0063 |
| Other | 610 (89) | 362 (86) | 248 (93) | |
| Donor age, median (95% CI) | 38 (20-64) | 41 (22-64) | 32 (20-52) | <.0001 |
| Graft source | ||||
| PBSC | 617 (90) | 365 (87) | 255 (96) | <.0001 |
| BM | 67 (10) | 55 (13) | 12 (4) | |
| Conditioning | ||||
| MAC | 272 (40) | 226 (54) | 46 (17) | <.0001 |
| RIC | 412 (60) | 191 (46) | 221 (83) | <.0001 |
95% CI, 95% confidence interval; BM, bone marrow; D, donor; HCT, allogeneic hematopoietic stem cell transplantation; MAC, myeloablative conditioning; MRD, matched related donor transplant; MUD, matched unrelated donor transplant; PBSC, peripheral blood stem cells; R, recipient; RIC, reduced intensity conditioning.
De novo AML in first complete remission (CR).
All other disease stages that did not correspond to AML in first CR, such as AML in second remission.